HSBC Holdings
VERV

HSBC Holdings’s Verve Therapeutics VERV Stock Holding History

HSBC Holdings’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,149
Closed -$307K – 3160
2025
Q2 		$307K Sell
27,149
-1,861
-6% -$10.6K ﹤0.01% 2423
2025
Q1 		$139K Buy
+29,010
New +$194K ﹤0.01% 2724
2024
Q3 		– Sell
-17,217
Closed -$80.2K – 3166
2024
Q2 		$80.2K Buy
+17,217
New +$108K ﹤0.01% 2772

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HSBC Holdings's VERV Position: Q3 2025 in Review

HSBC Holdings sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 27,149 shares — an estimated $307K sold.

HSBC Holdings first reported a position in VERV in Q2 2024 and held it in 3 quarters. The position peaked at $307K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • HSBC Holdings reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HSBC Holdings sold 27,149 Verve Therapeutics shares in Q3 2025, an estimated $307K.
  • HSBC Holdings first reported a position in Verve Therapeutics in Q2 2024 and held it in 3 quarters.
  • HSBC Holdings's Verve Therapeutics position peaked at $307K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.